Reboxetine: Its effects as measured by the social adaptation self- evaluation scale

Acta Psychiatrica Scandinavica, Supplement

Volumn 101, Issue 402, 2000, Pages 45-51

  Healy, David ^a  

^a Hergest Unit   (United Kingdom)

Author keywords

Emotional blunting; Flouxetine; Quality of life; Reboxetine; Social functioning

Indexed keywords

FLUOXETINE; PLACEBO; REBOXETINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; MORPHOLINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMITTER RELEASE; OUTCOMES RESEARCH; SELF EVALUATION; SOCIAL ADAPTATION; SOCIAL INTERACTION; WELLBEING; MAJOR DEPRESSION; MIDDLE AGED; MULTICENTER STUDY; PHARMACOKINETICS; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; MULTICENTER STUDIES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; SOCIAL ADJUSTMENT; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0033649199     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2000.02608.x     Document Type: Article

References (36)

1. 1. GARATTINI S. Experimental and clinical activity of antidepressant drugs. In HEALY D, DOOGAN D, eds. Psychotropic drug development. Social, economic and pharmacological aspects. London: Chapman & Hall, 1996:1-12.
2. 2. HEALY D. The antidepressant era. Boston: Harvard University Press, 1997.
3. 3. KIELHOLZ P. Die behandlung endogener depressionem mit psychopharmaka. Dtsch Med Wochenschr 1968;93:701-710.
4. 4. CARLSSON A. The rise of neuropsychopharmacology: impact on basic and clinical neuroscience. In HEALY D, ed. The psychopharmacologists. London: Chapman & Hall, 1996: 51-80.
5. 5. HEALY D. The structure of psychopharmacological revolutions. Psychiatr Dev 1987;5:349-376.
6. 6. HEALY D, MCMONAGLE T. Enhancement of social functioning as a therapeutic principle in the management of depressive disorders. J Psychopharmacol 1997;11:22-29.
7. 7. LURIE M. The enigma of isoniazid. In HEALY D, ed. The psychopharmacologists, vol 2. London: Lippincott-Raven, 1998:119-134.
8. 8. HEALY D, SAVAGE M. Reserpine exhumed. Br J Psychiatry 1998;172:376-378.
9. 9. HEALY D. Meta-analysis of trials comparing antidepressants with active placebos. Br J Psychiatry 1998;172:232-234.
10. 10. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
11. 11. BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:53-63.
12. 12. ZUNG WWK, DURHAM NC. A self-rating depression scale. Arch Gen Psychiatry 1965;12:61-70.
13. 13. BECH P. Clinical effects of selective serotonin reuptake inhibitors. In DAHL SG, GRAM LF, eds. Clinical pharmacology in psychiatry. Berlin: Springer-Verlag, 1989:82-93.
14. 14. BOSC M, DUBINI A, POLIN V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 1997;7: S57-S70.
15. 15. STOKER MJ, DUNBAR GC, BEAUMONT G. The SmithKline Beecham 'quality-of-life' scale: a validation and reliability study in patients with affective disorder. Qual Life Res 1992;1:385-395.
16. 16. TURNER R. Quality of life: experience with sertraline. Int Clin Psychqpharmacol 1994;9:27-31.
17. 17. TUYNMAN-QUA H, DE JONGHE F, MCKENNA S, HUNT S. Quality of Life in Depression Rating Scale. Ibero: Houten, 1992.
18. 18. ENDICOTT J, NEE J, HARRISON W, BLUMENTHAL R. Quality of life enjoyment and satisfaction questionnaire. Psychopharmacol Bull 1993;29:321-327.
19. 19. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 3rd edn rev. Washington DC: AMA, 1987.
20. 20. DUBINI A, BOSC M, POLIN V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997;7:S49-S56.
21. 21. MASSANA J, MOLLER H-J, BURROWS GD, MONTENEGRO RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999; 14:73-80.
22. 22. GUY A. In ECDEU assessment manual for psychopharmacology. Maryland: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, 1976:217-222.
23. 23. MONTGOMERY SA, ASBERG M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.
24. 24. BECH P. Quality of life instruments in depression. Eur Psychiatry 1997;12:194-198.
25. 25. KATSCHNIG H. How useful is the concept of quality of life in psychiatry. Curr Opin Psychiatry 1997;10:337-345.
26. 26. HEALY D. Reboxetine, fluoxetine and social functioning as an outcome measure in antidepressant trials: implications. Prim Care Psychiatr 1998;4:81-89.
27. 27. SIMON GE, VONKORFF M, HEILIGENSTEIN JH et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. J Am Med Assoc 1996;275:1897-1902.
28. 28. SOUETRE E, MARTIN P, LOZET H, MONTEBAN H. Quality of life in depressed patients: comparison of fluoxetine and major tricylic antidepressants. Int Clin Psychopharmacol 1996; 11:45-52.
29. 29. WHEATLEY DP, VAN MOFFAERT M, TIMMERMAN L, KREMER CM. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 1998;59:306-312.
30. 30. LYDIARD RB, STAHL SM, HERTZMAN M, HARRISON WM. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997;58:484-491.
31. 31. KOCSIS JH, ZISOOK S, DAVIDSON J et al. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry 1997;154:390-395.
32. 32. LONNQVIST J, SINTONEN H, SYVALAHTI E et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand 1994;89:363-369.
33. 33. KNUTSON B, WOLKOWITZ OM, COLE SW et al. Selective alteration of personality and social behaviour by serotonergic intervention. Am J Psychiatry 1998;155:373-379.
34. 34. JOYCE PR, MULDER RT, CLONINGER CR. Temperament predicts clomipramine and desipramine response in major depression. J Affect Disord 1994;30:35-46.
35. 35. FARDE L, GUSTAVSSON JP, JONSSON E. D2 dopamine receptors and personality traits. Nature 1997;380:590.
36. 36. BREIER A, KESTLER L, ADLER C et al. Dopamine D-2 receptor density and personal detachment in healthy subjects. Am J Psychiatry 1998;155:1440-1442.